Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of December 2025. The filing details a share repurchase executed on December 2, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on share repurchase activity and does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics.
- Shares Purchased: 200,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,783.00p; highest price paid was 1,827.00p.
- Average Price: Volume-weighted average price paid was 1,815.48p.
- Trading Venues: Purchases were executed across BATE, CHIX, and XLON.
- Treasury Holdings: Following this purchase, the Company holds 237,011,577 ordinary shares in treasury.
- Shares in Issue: 4,078,422,107 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 5.81% of total voting rights.
Material Changes vs. Prior Period
Since the commencement of the current buyback agreement on September 30, 2025, the Company has purchased an aggregate of 11,546,733 ordinary shares. The filing does not provide comparative financial performance data against prior periods.
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or management commentary regarding operational outlook. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the "Risk Factors" section of GSK's 2024 Annual Report on Form 20-F and its Q3 2025 Results. No unusual items or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the total remaining authorization under the buyback programme announced on September 30, 2025.
- Confirm the current market price relative to the 1,815.48p average purchase price.
- Review the "Risk Factors" in the 2024 Form 20-F for context on forward-looking statements.
- Check subsequent filings for updates on the total number of shares repurchased under the programme.